Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A

被引:10
作者
Huang, Kun [1 ]
Ai, Di [1 ]
Li, Gang [2 ]
Zhen, Yingzi [1 ]
Wang, Yan [3 ]
Zhang, Ningning [4 ]
Huo, Aihua [4 ]
Liu, Guoqing [1 ]
Chen, Zhenping [2 ]
Wu, Runhui [1 ]
机构
[1] Capital Med Univ, Beijing Childrens Hosp, Hematol Ctr, Natl Ctr Childrens Hlth, Nanlishi Rd 56, Beijing 100045, Peoples R China
[2] Capital Med Univ, Beijing Childrens Hosp, Beijing Pediat Res Inst, Hematol Dis Lab,Natl Ctr Childrens Hlth, Nanlishi Rd 56, Beijing 100045, Peoples R China
[3] Capital Med Univ, Beijing Childrens Hosp, Rehabil Dept, Natl Ctr Childrens Hlth, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Childrens Hosp, Radiol Ctr, Natl Ctr Childrens Hlth, Beijing, Peoples R China
关键词
bleeds; Factor VIII; haemophilia A; paediatrics; pharmacokinetics; prophylaxis; PHARMACOKINETIC-GUIDED PROPHYLAXIS; FACTOR-VIII LEVELS; BLEEDS;
D O I
10.1111/hae.14635
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction As standard care of severe haemophilia A (SHA), prophylaxis should be individualised. Aim This study aimed to investigate the effectiveness of this new-proposed individualised prophylaxis protocol. Methods Boys with SHA were enrolled and followed a PK-guided, trough-level escalating protocol of prophylaxis after a six-month observational period. In the next 2 years, clinical assessments including joint bleeds, ultrasound (US) scores and Haemophilia Joint Health Score (HJHS) in both sides of ankles, knees and elbows were conducted every 6 months as a scoring system, which determined whether the trough level's escalation. Adjustment of dosing regimen was based on WAPPS-Hemo. Results Fifty-eight SHA boys were finally analysed. Their age and bodyweight were 5.3(2.8,6.9) years and 21.5(16,25) kg. During the study, 47 escalations were conducted. At study exit, the patient number and proportion of different trough level groups were: < 1 IU/dl, 17.2% (10/58); 1-3 IU/dl, 53.5% (31/58); 3-5 IU/dl, 15.5% (9/58); > 5 IU/dl, 13.8% (8/58). Significantly reduced annualised bleeding rate [4(0,8) to 0(0,2), p < .0001] and annualised joint bleeding rate [2(0,4) to 0(0,.25), p < .0001] was observed at study exit as well as the continuous trend of increased zero bleeding proportion (ZBP) (27.6%-69.0%) and zero joint bleeding proportion (46.5%-81.3%). Besides, 85% (6/7) of the target joints vanished. Statistical improvements of US scores (p = .04) and HJHS (p = .02) were also reported at study exit. Conclusion Our results showed the effectiveness of our protocol based on individualised target trough level and emphasise the importance of personalised prophylaxis.
引用
收藏
页码:E209 / E218
页数:10
相关论文
共 27 条
[1]  
Ahlberg A., 1965, Acta Orthop Scand Suppl, P3, DOI DOI 10.3109/ORT.1965.36.SUPPL-77.01
[2]   Haemophilia [J].
Berntorp, Erik ;
Fischer, Kathelijn ;
Hart, Daniel P. ;
Mancuso, Maria Elisa ;
Stephensen, David ;
Shapiro, Amy D. ;
Blanchette, Victor .
NATURE REVIEWS DISEASE PRIMERS, 2021, 7 (01)
[3]   Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis [J].
Chowdary, Pratima ;
Fischer, Kathelijn ;
Collins, Peter W. ;
Cotterill, Amy ;
Konkle, Barbara A. ;
Blanchette, Victor ;
Pipe, Steven W. ;
Berntorp, Erik ;
Wolfsegger, Martin ;
Engl, Werner ;
Spotts, Gerald .
THROMBOSIS AND HAEMOSTASIS, 2020, 120 (05) :728-736
[4]   Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A [J].
Collins, P. W. ;
Blanchette, V. S. ;
Fischer, K. ;
Bjorkman, S. ;
Oh, M. ;
Fritsch, S. ;
Schroth, P. ;
Spotts, G. ;
Astermark, J. ;
Ewenstein, B. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (03) :413-420
[5]   Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes [J].
Croteau, Stacy E. ;
Wheeler, Allison P. ;
Khan, Osman ;
Haley, Kristina M. ;
Borst, Alexandra J. ;
Lattimore, Susan ;
Yeung, Cindy H. T. ;
Iorio, Alfonso .
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (02) :326-333
[6]   Clinical severity of haemophilia A: does the classification of the 1950s still stand? [J].
Den Uijl, I. E. M. ;
Bunschoten, E. P. Mauser ;
Roosendaal, G. ;
Schutgens, R. E. G. ;
Biesma, D. H. ;
Grobbee, D. E. ;
Fischer, K. .
HAEMOPHILIA, 2011, 17 (06) :849-853
[7]   Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels [J].
den Uijl, I. E. M. ;
Fischer, K. ;
van der Bom, J. G. ;
Grobbee, D. E. ;
Rosendaal, F. R. ;
Plug, I. .
HAEMOPHILIA, 2011, 17 (01) :41-44
[8]   Outcome in moderate haemophilia [J].
den Uij, Ingrid ;
Biesma, Douwe ;
Grobbee, Diederick ;
Fischer, Kathelijn .
BLOOD TRANSFUSION, 2014, 12 :S330-S336
[9]   Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study [J].
Feldman, BM ;
Pai, M ;
Rivard, GE ;
Israels, S ;
Poon, MC ;
Demers, C ;
Robinson, S ;
Luke, KH ;
Wu, JKM ;
Gill, K ;
Lillicrap, D ;
Babyn, P ;
McLimont, M ;
Blanchette, VS .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (06) :1228-1236
[10]   Diagnostic accuracy of point-of-care ultrasound for evaluation of early blood-induced joint changes: Comparison with MRI [J].
Foppen, W. ;
van der Schaaf, I. C. ;
Beek, F. J. A. ;
Mali, W. P. T. M. ;
Fischer, K. .
HAEMOPHILIA, 2018, 24 (06) :971-979